Suggested remit: To appraise the clinical and cost effectiveness of ibrutinib with rituximab within its marketing authorisation for untreated chronic lymphocytic leukaemia.
Status In progress
Process STA 2018
ID number 2708

Provisional Schedule

Expected publication 24 March 2021

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
18 February 2020 - 17 March 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
23 January 2020 In progress. In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance